Datamonitor's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.
Project Description:
Datamonitors' f-star GmbH Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by f-star GmbH since January 2007.
Scope:
– Provides intelligence on f-star GmbH's M&A, strategic partnerships and alliances, capital raising and private equity transactions. – Detailed reports of various financial transactions undertaken by f-star GmbH and its subsidiaries since 2007. – Information about key financial and legal advisors for f-star GmbH's financial deals transactions. – Financial deals tables and charts covering deal value and volumes trend, deal types and geography-based deal activity.
Highlights:
This report includes f-star GmbH's contact information and business summary, tables, graphs, a list of partners and targets, a breakdown of financial and legal advisors, deal types, top deals by deal value, detailed deal reports, and descriptions and contact details of the partner, target, investor, and vendor firms, where disclosed.
The profile also includes detailed deal reports for all M&A, private equity, public offering, venture financing, partnership and divestment transactions undertaken by f-star GmbH. These deal reports contain information about target company financials, sources of financing, method of payment, deal values, and advisors for various parties, where disclosed.
Reasons to Purchase:
– Access comprehensive financial deals data along with charts and graph covering M&A, private equity, and partnerships and alliances. – Form an independent opinion about f-star GmbH’s growth strategies through the organic and inorganic activities undertaken since 2007. – Track your competitors’ business structure and growth strategies.
Our reports have been used by over 10K customers, including:
Glomerulonephritis Disease - Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Glomerulonephritis Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Glomerulonephritis Clinical trials scenario.This report provides top line data relating to the clinical...
Dermatomyositis Disease - Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Dermatomyositis Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Dermatomyositis Clinical trials scenario.This report provides top line data relating to the clinical trials...
242 pages •
By The Business Research Company
• Dec 2020
CAR-T Therapy Global Market Opportunities And Strategies To 2030: COVID-19 Impact and Recovery provides the strategists, marketers and senior management with the critical information they need to assess the global CAR-T Therapy market. Description: Where is the largest and fastest growing market for the CAR-T therapy...
Aneurysm Disease - Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Aneurysm Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Aneurysm Clinical trials scenario. This report provides top line data relating to the clinical trials on Aneurysm. Report...
Leiomyosarcoma Disease - Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Leiomyosarcoma Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Leiomyosarcoma Clinical trials scenario. This report provides top line data relating to the clinical trials on...
232 pages •
By BioInformant Worldwide, L.L.C.
• Dec 2020
CAR-T cell therapy is a remarkably promising treatment for cancer patients. It is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as “living drugs.” T-cells...
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.